---
title: "VistaGen says Phase 2 repeat-dose fasedienol study in social anxiety disorder shows favorable safety, efficacy signals"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295108318.md"
description: "VistaGen Therapeutics reported favorable safety and efficacy signals from a Phase 2 study of fasedienol nasal spray for social anxiety disorder. The trial met safety objectives with tolerability comparable to single doses. Efficacy data favored fasedienol over placebo, particularly in a severe subgroup, supporting potential FDA discussions on a registrational pathway."
datetime: "2026-08-06T12:34:37.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295108318.md)
  - [en](https://longbridge.com/en/news/295108318.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295108318.md)
generator: "portal-rs"
---

# VistaGen says Phase 2 repeat-dose fasedienol study in social anxiety disorder shows favorable safety, efficacy signals

-   VistaGen released topline results from an exploratory Phase 2 repeat-dose study of fasedienol nasal spray for acute social anxiety triggered by public speaking. \* Safety met the study objective, with repeat dosing showing tolerability comparable to a single dose and no new safety issues. \* Efficacy signals favored fasedienol over placebo on the main anxiety measure, though the trial was not designed to show statistically significant differences. \* A prespecified very severe subgroup showed a nominally significant improvement with fasedienol, supporting FDA discussions on a potential registrational pathway. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VistaGen Therapeutics Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [VTGN.US](https://longbridge.com/en/quote/VTGN.US.md)

## Related News & Research

- [VistaGen reports Phase 3 fasedienol shows positive efficacy signal in severe social anxiety subgroup analysis](https://longbridge.com/en/news/298595046.md)
- [VistaGen Therapeutics holds annual shareholder meeting](https://longbridge.com/en/news/298713264.md)
- [Definium Therapeutics to present Phase 3 topline data for DT120 in MDD, GAD at Psych Congress 2026](https://longbridge.com/en/news/298582158.md)
- [Definium Therapeutics to present Phase 3 Panorama topline data for DT120 in generalized anxiety disorder Sept. 14](https://longbridge.com/en/news/298839610.md)
- [Modine VP, CHRO Brian Jon Agen disposes of 4,306 common shares worth $776,371.80](https://longbridge.com/en/news/298954559.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**